Monday, 4 February 2019

Antibiotic Market 2019 Anticipated to Witness Rapid Growth in Near Year 2024


4 February 2019: The Global Antibiotic Market is expected to witness rapid growth in the near future due to the development of novel products and rising investment in research & development of advanced antibiotic. Additionally, development of thirty-seven highly advanced molecules in the U.S. region coupled with phase II clinical trials are expected to foster market growth over the forecast period.


Favorable governmental regulation, reforms and legislations such as the Generating Antibiotics Incentives Now (GAIN) Act are predicted to drive approval rate, thus propelling market growth further. Globally, the antibiotic market is predicted to grow at a substantial CAGR in forecast period, providing numerous opportunities for market players to invest in research and development in the antibiotic market.


The Generating Antibiotics Incentives Now (GAIN) Act has enabled production of advanced set of therapies against antibiotic resistant pathogens. These factors are expected to play a major role for the robust growth of market over the forecast period. Growing demand of antibiotic drugs is attributed to rising prevalence of infectious diseases in both developing and developed economies across the globe, in the recent years. Additionally, rising number of manufacturers of antibiotic drugs and significant R&D activities in the market are expected to fuel market growth in the upcoming years.
Infection diseases such as Diarrhea is considered as one of the Major cause of high mortality rate among children, particularly in the developing and underdeveloped economies all around the globe. Increasing use of antibiotic drugs to prevent this morbidity is anticipated to augment market demand over the forecast period. Increasing number of cases related to other infectious diseases such as HIV, pneumonia, malaria, and tuberculosis is further propelling market growth since last couple of decades.


The monoclonal antibodies is considered as one of the fastest growing segment in the antibiotics market with substantial revenue generation in the last couple of years. Numerous benefits of monoclonal antibodies over its counter parts is considered as major driving factor for the growth of monoclonal antibodies market segment. Growing prevalence of pneumonia, blood stream infections, and urinary tract infections (UTI) are predicted to boost the demand of carbapenems class of antibiotics.
The key players in the antibiotics market are Pfizer Incorporations, Janssen Pharmaceuticals, Inc., Abbott Laboratories, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company Co., and Astellas Pharma Incorporations.

Get in touch
At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact Person:
Ryan Manuel
Research Support Specialist, USA

Million Insights
Office No. 302, 3rd Floor, Manikchand Galleria,
Model Colony, Shivaji Nagar, Pune, MH, 411016 India
tel: 91-20-65300184


No comments:

Post a Comment